Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-α-reductase type 2 is important for prostate cancer development

Cancer Research

Volumn 66, Issue 22, 2006, Pages 11077-11083

  Lindström, Sara ^a   Wiklund, Fredrik ^b   Adami, Hans Olov ^b   Bälter, Katarina Augustsson ^b   Adolfsson, Jan ^b   Grönberg, Henrik ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOCHROME P450; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HAPLOTYPE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE; VARIATION (GENETICS);

EID: 33845288374     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3024     Document Type: Article

References (27)

1. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 2004;129:65-73.
2. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35.
3. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003;149:469-77.
4. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004;92:255-64.
5. Lange EM, Chen H, Brierley K, et al. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:439-42.
6. Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-8.
7. Lindström S, Zheng SL, Wiklund F, et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006 Sep 22 (Epub ahead of print).
8. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-54.
9. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
10. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
11. Jurinke C, van den Boom D, Cantor CR, Köster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2002;187:179-92.
12. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
13. Besag J, Clifford P. Sequential Monte Carlo p-values. Biometrika 1991;78:301-4.
14. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993;49:865-72.
15. Hayes VM, Severi G, Eggleton SA, et al. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 2005;14:993-6.
16. Freedman ML, Pearce CL, Penney KL, et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 2005;76:82-90.
17. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003;97:1894-903.
18. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
19. Douglas JA, Zuhlke KA, Beebe-Dimmer J, et al. Identifying susceptibility genes for prostate cancer - a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-β. Cancer Epidemiol Biomarkers Prev 2005;14:2035-9.
20. Morgentaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6.
21. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7.
22. Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density, and androgen receptor gene polymorphism in prostate cancer. J Urol 2003;169:1312-5.
23. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20:605-8.
24. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670-5.
25. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-8.
26. San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006;175:1341-5 DISCUSSION 1345-6.
27. Stattin P, Johansson R, Damber JE, et al. Non-systematic screening for prostate cancer in Sweden - survey from the National Prostate Cancer Registry. Scand J Urol Nephrol 2003;37:461-5.